VIR Stock Overview
A commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Vir Biotechnology, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$11.37 |
52 Week High | US$27.48 |
52 Week Low | US$7.61 |
Beta | 0.46 |
1 Month Change | 40.37% |
3 Month Change | 10.39% |
1 Year Change | -56.44% |
3 Year Change | -75.15% |
5 Year Change | n/a |
Change since IPO | -18.90% |
Recent News & Updates
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates
May 05Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
May 03Recent updates
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates
May 05Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
May 03Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Feb 28Sticking With Vir Biotechnology
Jan 17Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%
Aug 07Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive
Jul 24Analysts Just Shaved Their Vir Biotechnology, Inc. (NASDAQ:VIR) Forecasts Dramatically
Feb 28Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Could Be 26% Below Their Intrinsic Value Estimate
Jan 07Vir Biotechnology: Focus On Hepatitis B Development Could End Up Paying Off
Oct 12Vir Biotech gains 12% as U.S. govt. inks multi-year deal worth up to $1B
Oct 04Vir begins dosing in mid-stage study of VIR-2218, VIR-3434 for hepatitis D virus
Sep 22Vir Biotechnology falls 15% on Q2 revenue miss impacted by ~$400M for potential write-offs
Aug 09Vir: Biotechnology's Best Near-Term Capital Gain Prospect
Jul 27Vir Biotechnology announces transition of chief scientific officer
Jul 14Shareholder Returns
VIR | US Biotechs | US Market | |
---|---|---|---|
7D | 13.5% | 0.7% | 1.2% |
1Y | -56.4% | 5.0% | 27.7% |
Return vs Industry: VIR underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: VIR underperformed the US Market which returned 27.7% over the past year.
Price Volatility
VIR volatility | |
---|---|
VIR Average Weekly Movement | 8.7% |
Biotechs Industry Average Movement | 11.2% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.2% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: VIR's share price has been volatile over the past 3 months.
Volatility Over Time: VIR's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | 587 | Marianne De Backer | www.vir.bio |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.
Vir Biotechnology, Inc. Fundamentals Summary
VIR fundamental statistics | |
---|---|
Market cap | US$1.39b |
Earnings (TTM) | -US$539.44m |
Revenue (TTM) | US$79.60m |
19.4x
P/S Ratio-2.9x
P/E RatioIs VIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VIR income statement (TTM) | |
---|---|
Revenue | US$79.60m |
Cost of Revenue | US$507.81m |
Gross Profit | -US$428.21m |
Other Expenses | US$111.22m |
Earnings | -US$539.44m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.96 |
Gross Margin | -537.97% |
Net Profit Margin | -677.69% |
Debt/Equity Ratio | 0% |
How did VIR perform over the long term?
See historical performance and comparison